Literature DB >> 19357115

Molecular analyses of the LRRK2 gene in European and North African autosomal dominant Parkinson's disease.

S Lesage, C Condroyer, A Lannuzel, E Lohmann, A Troiano, F Tison, P Damier, S Thobois, A-M Ouvrard-Hernandez, S Rivaud-Péchoux, C Brefel-Courbon, A Destée, C Tranchant, M Romana, L Leclere, A Dürr, A Brice.   

Abstract

BACKGROUND: Mutations in the leucine-rich-repeat kinase 2 (LRRK2) gene have been identified in families with autosomal dominant Parkinson's disease (ADPD), the most common of which is the p.G2019S substitution that has been found at varying frequencies worldwide. Because of the size of the LRRK2 gene, few studies have analysed the entire gene in large series of ADPD families.
METHODS: We performed extensive mutation analyses of all 51 coding exons of the LRRK2 gene in index cases from 226 Parkinson's disease families compatible with autosomal dominant inheritance, mostly from France (n = 182) and North Africa (n = 14).
RESULTS: We found 79 sequence variants, 29 of which were novel. Eight potentially or proven pathogenic mutations were found in 22 probands (9.7%). There were four novel amino acid substitutions that are potentially pathogenic (p.S52F, p.N363S, p.I810V, p.R1325Q) and two novel variants, p.H1216R and p.T1410M, that are probably not causative. The common p.G2019S mutation was identified in 13 probands (5.8%) including six from North Africa (43%). The known heterozygous p.R1441H and p.I1371V mutations were found in two probands each, and the p.E334K variant was identified in one single patient. Most potentially or proven pathogenic mutations were located in the functional domains of the Lrrk2 protein.
CONCLUSION: This study leads us to conclude that LRRK2 mutations are a common cause of autosomal dominant Parkinson's disease in Europe and North Africa.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19357115     DOI: 10.1136/jmg.2008.062612

Source DB:  PubMed          Journal:  J Med Genet        ISSN: 0022-2593            Impact factor:   6.318


  14 in total

1.  Lrrk2 p.Q1111H substitution and Parkinson's disease in Latin America.

Authors:  Ignacio F Mata; Greggory J Wilhoite; Dora Yearout; Justin A Bacon; Mario Cornejo-Olivas; Pilar Mazzetti; Victoria Marca; Olimpio Ortega; Oscar Acosta; Carlos Cosentino; Luis Torres; Angel C Medina; Carolina Perez-Pastene; Fernando Díaz-Grez; Carles Vilariño-Güell; Pablo Venegas; Marcelo Miranda; Osvaldo Trujillo-Godoy; Luis Layson; Rodrigo Avello; Elena Dieguez; Victor Raggio; Federico Micheli; Claudia Perandones; Victoria Alvarez; Juan Segura-Aguilar; Matthew J Farrer; Cyrus P Zabetian; Owen A Ross
Journal:  Parkinsonism Relat Disord       Date:  2011-05-31       Impact factor: 4.891

2.  Screening LRRK2 gene mutations in patients with Parkinson's disease in Ghana.

Authors:  Roberto Cilia; Francesca Sironi; Albert Akpalu; Momodou Cham; Fred Stephen Sarfo; Tiziana Brambilla; Alba Bonetti; Marianna Amboni; Stefano Goldwurm; Gianni Pezzoli
Journal:  J Neurol       Date:  2011-08-14       Impact factor: 4.849

3.  Association of LRRK2 exonic variants with susceptibility to Parkinson's disease: a case-control study.

Authors:  Owen A Ross; Alexandra I Soto-Ortolaza; Michael G Heckman; Jan O Aasly; Nadine Abahuni; Grazia Annesi; Justin A Bacon; Soraya Bardien; Maria Bozi; Alexis Brice; Laura Brighina; Christine Van Broeckhoven; Jonathan Carr; Marie-Christine Chartier-Harlin; Efthimios Dardiotis; Dennis W Dickson; Nancy N Diehl; Alexis Elbaz; Carlo Ferrarese; Alessandro Ferraris; Brian Fiske; J Mark Gibson; Rachel Gibson; Georgios M Hadjigeorgiou; Nobutaka Hattori; John P A Ioannidis; Barbara Jasinska-Myga; Beom S Jeon; Yun Joong Kim; Christine Klein; Rejko Kruger; Elli Kyratzi; Suzanne Lesage; Chin-Hsien Lin; Timothy Lynch; Demetrius M Maraganore; George D Mellick; Eugénie Mutez; Christer Nilsson; Grzegorz Opala; Sung Sup Park; Andreas Puschmann; Aldo Quattrone; Manu Sharma; Peter A Silburn; Young Ho Sohn; Leonidas Stefanis; Vera Tadic; Jessie Theuns; Hiroyuki Tomiyama; Ryan J Uitti; Enza Maria Valente; Simone van de Loo; Demetrios K Vassilatis; Carles Vilariño-Güell; Linda R White; Karin Wirdefeldt; Zbigniew K Wszolek; Ruey-Meei Wu; Matthew J Farrer
Journal:  Lancet Neurol       Date:  2011-08-30       Impact factor: 44.182

4.  Structural and functional in silico analysis of LRRK2 missense substitutions.

Authors:  Fernando Cardona; Marta Tormos-Pérez; Jordi Pérez-Tur
Journal:  Mol Biol Rep       Date:  2014-02-02       Impact factor: 2.316

Review 5.  Genetics in Parkinson disease: Mendelian versus non-Mendelian inheritance.

Authors:  Dena G Hernandez; Xylena Reed; Andrew B Singleton
Journal:  J Neurochem       Date:  2016-04-18       Impact factor: 5.372

Review 6.  Genetic etiology of Parkinson disease associated with mutations in the SNCA, PARK2, PINK1, PARK7, and LRRK2 genes: a mutation update.

Authors:  Karen Nuytemans; Jessie Theuns; Marc Cruts; Christine Van Broeckhoven
Journal:  Hum Mutat       Date:  2010-07       Impact factor: 4.878

7.  Genomic ancestry of North Africans supports back-to-Africa migrations.

Authors:  Brenna M Henn; Laura R Botigué; Simon Gravel; Wei Wang; Abra Brisbin; Jake K Byrnes; Karima Fadhlaoui-Zid; Pierre A Zalloua; Andres Moreno-Estrada; Jaume Bertranpetit; Carlos D Bustamante; David Comas
Journal:  PLoS Genet       Date:  2012-01-12       Impact factor: 5.917

Review 8.  Splicing: is there an alternative contribution to Parkinson's disease?

Authors:  Valentina La Cognata; Velia D'Agata; Francesca Cavalcanti; Sebastiano Cavallaro
Journal:  Neurogenetics       Date:  2015-05-16       Impact factor: 2.660

9.  Evaluating LRRK2 genetic variants with unclear pathogenicity.

Authors:  Fathima Shaffra Refai; Shin Hui Ng; Eng-King Tan
Journal:  Biomed Res Int       Date:  2015-03-02       Impact factor: 3.411

10.  Expression analysis of Lrrk1, Lrrk2 and Lrrk2 splice variants in mice.

Authors:  Florian Giesert; Andreas Hofmann; Alexander Bürger; Julia Zerle; Karina Kloos; Ulrich Hafen; Luise Ernst; Jingzhong Zhang; Daniela Maria Vogt-Weisenhorn; Wolfgang Wurst
Journal:  PLoS One       Date:  2013-05-10       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.